Senior Scientific LLC
Senior Scientific LLC
News Article | May 11, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, today announced the addition of three new members to its leadership team. Ellen Ridge has joined as Senior Vice President of Operations; Abraham Scaria, Ph.D., has joined as Vice President of Ophthalmology; and in July, Andrew M. Scharenberg, M.D., will join as Chief Scientific Officer and Vice President of Hematology. These additions reflect Casebia’s ongoing commitment to transform the lives of patients with a wide range of inherited diseases. “Ellen, Abraham, and Andy all bring deep expertise and talent in critical areas,” said James W. Burns, Ph.D., President and Chief Executive Officer of Casebia. “Given our ambitious objectives, I am confident in these new executives’ abilities to push this vital research and further scale our company in our quest to help patients.” Casebia was founded to harness the potential of CRISPR/Cas9 gene-editing technology and develop new medicines for people with inherited diseases. The company is concentrating its early efforts on making an impact in the areas of ophthalmology, non-malignant hematology, and autoimmune disease, followed by cardiovascular disease and hearing loss. The addition of these three senior leaders, with their diverse talents and expertise, will help move those research programs closer to human clinical trials. Ridge is a seasoned executive and veteran of the Cambridge biotechnology community. She joins Casebia from Intarcia Therapeutics Inc., where she served as Vice President for the Project Management Office. Ridge spent more than 20 years at Genzyme, where she rose through several different management positions before becoming Vice President of Enterprise Risk Management. In this role, Ridge designed and implemented Genzyme’s initial enterprise risk management process. She earned her Bachelor of Science degree in biology from the University of Massachusetts and holds a Master in Business Administration from Bentley University. In her role as Senior Vice President of Operations, Ridge will leverage her extensive experience with drug development, general management, and matrix management. Scaria has more than 20 years of experience in gene therapy, ranging from discovery research to clinical trials. For much of his career Scaria has specialized in viral vectors and ocular gene therapy, having served as Senior Scientific Director of Gene Therapy and Ophthalmology at Genzyme, and subsequently Sanofi. He most recently served as Head of Gene Therapy Research at Sanofi. He earned his Master of Science from the University of Bombay, India and his doctorate in biochemistry and molecular biology from Indiana University School of Medicine. As Vice President for Ophthalmology, Scaria will oversee Casebia’s efforts to develop breakthrough therapies for inherited retinal diseases. Scharenberg—who will join Casebia on July 1—is a widely respected physician-scientist with expertise in gene therapy and gene editing. Currently, Scharenberg is an attending physician at Seattle Children’s Hospital and Principal Investigator in the Center for Immunity and Immunotherapies at Seattle Children’s Research Institute. In addition, he also serves as Co-director of the Program in Cell and Gene Therapy at Seattle Children’s Hospital, a professor in the Department of Pediatrics and adjunct professor in the Department of Immunology at the University of Washington School of Medicine, and a member of the Transplantation Biology Consortium Program at Fred Hutchinson Cancer Research Center. He earned his Bachelor of Science in biochemistry from Indiana University and his medical degree from the University of North Carolina School of Medicine. As Chief Scientific Officer, Scharenberg will direct research strategy and innovation. Additionally, he will lead Casebia’s hematology research group. About Casebia Therapeutics Casebia Therapeutics is a novel joint venture between Bayer and CRISPR Therapeutics, focused on discovering, developing and commercializing new CRISPR/Cas9-based breakthrough therapeutics to treat the genetic causes of bleeding disorders, autoimmune disease, blindness, hearing loss, and heart disease. Formed in the first quarter of 2016, the company began operations in the U.S. in August of 2016. Casebia has access to gene-editing technology from CRISPR Therapeutics in specific disease areas, as well as access to protein engineering expertise and relevant disease know-how through Bayer. Casebia is a free-standing entity, equally owned by Bayer and CRISPR Therapeutics, with its own scientific leadership and management team. The company’s Board of Directors has equal composition from Bayer and CRISPR Therapeutics. Casebia’s primary base of research operations is in Cambridge, MA, with a second site in San Francisco, CA. For more information, please visit www.casebia.com.
News Article | May 18, 2017
PITTSBURGH, PA--(Marketwired - May 18, 2017) - Avere Systems, a leading provider of hybrid cloud enablement solutions, announced today that BioTeam, Inc. is incorporating Avere FXT Edge filers into its Convergence Lab, a testing environment hosted at the Texas Advanced Computing Center (TACC), in Austin, Texas. In cooperation with vendors and TACC, BioTeam utilizes the lab to evaluate solutions for its clients by standing up, configuring and testing new infrastructure under conditions relevant to life sciences in order to deliver on its mission of providing objective, vendor agnostic solutions to researchers. The life sciences community is producing increasingly large amounts of data from sources ranging from laboratory analytical devices, to research, to patient data, which is putting IT organizations under pressure to support these growing workloads. Avere's technology offers life science organizations the ability to flexibly process and store these growing datasets where it makes the most sense -- at performance levels that help to improve the rate of discovery. Avere Edge filers allow seamless integration of multiple storage destinations, including multiple public clouds and on-premises data centers, increasing the options that organizations like BioTeam can provide its customers for data center optimization. BioTeam plans on utilizing the FXT filers to test burst buffer workloads and hybrid storage strategies for life sciences data and workloads in order to develop effective recommendations for their customers under the right conditions. Avere's technology provides many world-renowned life science research facilities with flexibility and performance benefits, in addition to the ability to support the large data sets common to BioIT workflows. By reducing the dependency on traditional storage and facilitating modernization with hybrid cloud infrastructures, Avere also helps organizations keep their IT costs in check. The BioTeam Lab takes an integrative approach to streamlining computer-aided research from the lab bench to knowledge. Solutions are driven by BioTeam's clients and tailored to meet the scientific needs of the organization. Inside the lab, BioTeam works with vendors to understand the end-to-end experience of using their technologies and handles everything including the racking, installations, configuration, testing and integration, vendor communication and return shipping. Remote access to the lab is available from virtually any location with an internet connection. TACC provides the space, power, cooling, connectivity, support and deep collaboration on lab projects. "BioTeam is a fast-growing consulting company that is comprised of a highly cross-functional and creative group of scientists and engineers. Our unique cross section of experience allows us to enable computer-aided discovery in life sciences by creating and adapting IT infrastructure and services to fit the scientific goals of the organizations we work with," said Ari Berman, Vice President and General Manager of Consulting, BioTeam. "As part of our larger suite of hardware and software, having Avere in our lab gives us the hands-on ability to test Avere-based hybrid storage scenarios in a controlled and optimized life sciences environment, utilizing real workloads. These scenarios will allow BioTeam to understand where Avere technology best fits in the life sciences and healthcare domain and will allow us to innovate next-generation strategies for storage and analytics workflows. Having this opportunity allows us to deepen our understanding of the overall storage landscape and to be able to recommend fit for purpose solutions to our customers." "Working with BioTeam is a natural fit for Avere. Our technology has a solid track record of helping life science organizations leverage the cloud for large workloads for both cloud compute and storage resources," said Jeff Tabor, Senior Director of Product Management and Marketing at Avere Systems. "We look forward to collaborating with the BioTeam and continuing to help the industry effectively integrate cloud into their data center strategies and seamlessly use multiple cloud vendors." Next week at the BioIT World Conference in Boston, BioTeam and Avere will co-present "Freeing Data: How to Win the War with Hybrid Clouds." BioTeam Senior Scientific Consultant Adam Kraut and Avere CEO Ron Bianchini will take the stage on May 25, 2017 at 12:20pm ET. Avere Systems is exhibiting at the show, booth #536, from May 23 - 25, 2017. About Avere Systems Avere helps enterprise IT organizations enable innovation with high-performance data storage access, and the flexibility to compute and store data where necessary to match business demands. Customers enjoy easy reach to cloud-based resources, without sacrificing the consistency, availability or security of enterprise data. A private company based in Pittsburgh, Pennsylvania, Avere is led by industry experts to support the demanding, mission-critical hybrid cloud systems of many of the world's most recognized companies and organizations. Learn more at www.averesystems.com. About BioTeam, Inc. BioTeam, Inc. has a well-established history of providing complete, and forward-thinking solutions to the life sciences. With a cross-section of expertise that includes classical laboratory scientific training, applications development, informatics, large data center installations, HPC, enterprise and scientific network engineering, and high-volume as well as high-performance storage, BioTeam leverages the right technologies customized to its client's unique needs in order to enable them to reach their scientific objectives. For more information, please visit the company website. About Texas Advanced Computing Center TACC designs and deploys the world's most powerful advanced computing technologies and innovative software solutions to enable researchers to answer complex questions like these and many more. Every day, researchers rely on our computing experts and resources to help them gain insights and make discoveries that change the world. Find out more at https://www.tacc.utexas.edu/.
News Article | May 18, 2017
Nearly 32 million adults in the United States (13 percent of the U.S. population aged 18 and older) consumed more than twice the number of drinks considered binge drinking on at least one occasion, according to a 2013 survey that asked about past-year drinking. This higher level of drinking is associated with increased health and safety risks. A report of the findings is online in the American Journal of Preventive Medicine. The study was conducted by researchers at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health. "This important study reveals that a large number of people in the United States drink at very high levels and underscores the dangers associated with such 'extreme' binge drinking," said NIAAA Director George F. Koob, Ph.D. "Of the nearly 90,000 people who die from alcohol each year, more than half, or 50,000, die from injuries and overdoses associated with high blood alcohol levels." Binge drinking, defined as having four or more drinks on an occasion for women, or five or more drinks on an occasion for men, can produce blood alcohol levels greater than 0.08 percent, which is the legal limit for driving in the United States. Reaching this level is well known to increase the risk of harms to the drinker and others. However, evidence suggests that many people drink far beyond four or five drinks per occasion, defined as extreme binge drinking. The current study analyzed three levels of past-year binge drinking -- Levels I, II, and III. These levels were defined as four to seven drinks, eight to 11 drinks, and 12 or more drinks on a single occasion for women; and five to nine drinks, 10-14 drinks, and 15 or more drinks on a single occasion for men. Researchers, led by Ralph Hingson, Sc.D., director of the NIAAA Division of Epidemiology and Prevention Research, analyzed data from two waves of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), which is a series of large epidemiologic surveys that examine alcohol use and its co-occurrence with drug use and related psychiatric conditions. In the 2001-2002 and 2012-2013 waves of NESARC, 42,748 and 36,083 U.S. adults, respectively, reported the maximum number of drinks they consumed on any day in the past year. The researchers found that in the 2012-2013 survey, 39 percent of adult males and 27 percent of adult females reported Level I binge drinking during the previous year. Eleven percent of males reported Level II binge drinking (two times the binge drinking threshold for adult males) at least once in the past year, and 7 percent reported Level III binge drinking (three times the binge threshold) at least once in the past year. Five percent of females reported Level II binge drinking (two times the binge drinking threshold for adult females) at least once in the past year, and 3 percent reported Level III binge drinking (three times the binge threshold) at least once in the past year. After controlling for age, race, sex, marital status, education, drug use, and smoking, compared to people who did not binge drink, people who drank at the various binge levels were much more likely to experience an alcohol-related emergency department visit; have an alcohol use disorder; be injured because of drinking; be arrested or have legal problems resulting from alcohol use; or be the driver in an alcohol-related traffic crash. Compared to non-binge-drinkers, Level I binge drinkers were 13 times more likely, Level II binge drinkers were 70 times more likely, and Level III binge drinkers were 93 times more likely, to have an alcohol-related emergency department visit. Comparing data from the 2001-2002 and 2012-2013 NESARC waves, the researchers found that the prevalence of drinking at levels two and three times or more the standard binge thresholds in the past year was significantly higher in the most recent NESARC wave, suggesting that more adults are engaging in extreme binge drinking now than a decade earlier. "As a society, we are justifiably concerned about extreme binge drinking among underage individuals and college students. This study indicates that other groups in the U.S. population also engage in this harmful behavior and are at increased risk for adverse consequences," says Hingson. Extreme binge drinking was particularly common among study participants who used other drugs. This is a concern because combining alcohol with other drugs can increase the risk of injuries and overdose deaths. "Drinking at such high levels can suppress areas of the brain that control basic life-support functions such as breathing and heart rate, thereby increasing one's risk of death," said senior author, Aaron White, Ph.D., Senior Scientific Advisor to the NIAAA Director. "The risk increases further if other sedative drugs, particularly opioids or benzodiazepines, are added to the mix." The researchers noted that their findings highlight the need to identify interventions to reduce extreme binge drinking and its negative consequences. Additional research is needed to determine how questions about peak alcohol consumption levels can be valuable in screening for alcohol misuse, as well as in assessing gender-specific risk factors and harms for drinking at extreme levels.
News Article | June 14, 2017
NEW YORK--(BUSINESS WIRE)--Manhattan Scientifics Inc. (OTCQB: MHTX) announced today that it will host a conference call for MHTX investors at 12:00 pm Eastern Time on Friday, June 16, 2017 to provide an update and briefing on the pending Imagion Biosystems IPO (IBX). There will not be a Q&A Session and participants will be restricted to listening mode. Participants can dial into the call using the following instruction. A replay of the call will be posted on the company website http://mhtx.com. Manhattan Scientific’s affiliate company, Imagion Biosystems Limited, formerly known as Senior Scientific, LLC, has filed a prospectus with the Australian Securities and Investment Commission and has applied to the Australian Securities Exchange for an Initial Public Offering ("IPO") to raise up to A$12 million at A$0.20 per share. You can read the Imagion offering prospectus on Imagion’s website: https://imagionbiosystems.com/investor-relations/ “go to prospectus”. Funds raised in the IPO are expected to be used in Imagion’s efforts to move to clinical product development followed by human clinical testing. Assuming the closing of the IPO and the issuance of additional shares to Manhattan Scientifics from the conversion of a note, Manhattan Scientifics is projected to own approximately 64.1 million IBX shares equal to approximately 29.2% of Imagion. Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of transformative technologies. Imagion Biosystems Limited (www.imagionbiosystems.com) is an Australian corporation with underlying business operations largely focused on research and development of the MagSense™ SPMR technology, including both the technology employed in the measuring instrument and various formulations of nanoparticles for detecting specific types of diseases. This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
News Article | June 15, 2017
SAN DIEGO, June 15, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced a presentation at the International Society for Stem Cell Research (ISSCR) 2017 Annual Meeting in Boston. ViaCyte is developing novel stem cell-derived islet replacement therapies for insulin-requiring diabetes. The presentation at ISSCR details methods of generating mature glucose-responsive insulin-producing beta cells in vitro. The work presented is an extension of the first ever report of generating glucose-responsive beta-like cells in vitro from pluripotent stem cells, published September 2014 in Nature Biotechnology by Alireza Rezania, Ph.D., and colleagues. "We believe that these in vitro cells have now acquired some cardinal features of naturally occurring mature human pancreatic beta cells. The ability to create mature pancreatic beta cells in vitro is valuable not only for research into cell replacement therapies but also for disease modeling and drug testing," said Dr. Rezania, Senior Scientific Director at ViaCyte. "In our study, detailed kinetic characterization of the generated cells shows that insulin secretion is acutely coupled to glucose levels. I look forward to discussing these results with the stem cell community as we work to establish the metrics that define the mature pancreatic beta cell in vitro."
Senior Scientific Llc | Date: 2015-06-01
A method of producing a metal carboxylate compound, comprising (a) combining an organometallic compound with a stoichiometric excess of carboxylic acid; (b) heating the combination to a temperature sufficient to lead to thermal decomposition of the organometallic compound, until the metal carboxylate compound is formed; (c) cooling the combination.
Senior Scientific LLC | Date: 2015-04-06
Apparatuses and methods for removing magnetic particles from suspensions are described. One embodiment of the apparatus is called a magnetic needle.
Senior Scientific LLC | Date: 2015-06-19
Embodiments of the invention provide methods and apparatuses suitable for use with magnetic relaxometry measurements. Embodiments can include one or more of atomic magnetometers, synthetic gradiometers, specific magnetizing coil configurations, cryoswitches, shielded enclosures, and field compensation systems.
Senior Scientific LLC | Date: 2016-03-28
The present invention provides methods and apparatuses for detecting, measuring, or locating cells or substances present in even very low concentrations in vivo in subjects, using targeted magnetic nanoparticles and special magnetic systems. The magnetic systems can comprise magnetizing subsystems and sensors subsystems, including as examples SQUID sensors and atomic magnetometers. The magnetic systems can detect, measure, or location particles preferentially internalized by cells due to the action of antibodies, proteins, macromolecules, or nutrients required for cellular metabolism. Example magnetic systems are capable of detecting sub-nanogram amounts of these nanoparticles.
Senior Scientific LLC | Date: 2015-09-22
Methods and apparatuses for detecting substances circulating in a patients blood are described. The substances, such as tumor cells, are targeted with nanoparticles labeled such that they preferentially bind with the substance of interest. As the nanoparticle-labeled substance circulates, it can pass near a magnetic relaxometry system that can detect the substance by detecting the nanoparticles bound to it.